Halozyme Therapeutics (FRA:RV7) YoY EBITDA Growth : 43.04% (As of Mar. 2025)

View and export this data going back to 2004. Start your Free Trial

What is Halozyme Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Halozyme Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was 43.04%.

Halozyme Therapeutics's EBITDA per Share for the three months ended in Mar. 2025 was €1.23.

Halozyme Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for Halozyme Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halozyme Therapeutics YoY EBITDA Growth Chart

Halozyme Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

YoY EBITDA Growth

Get a 7-Day Free Trial

351.84

75.70

35.60

45.80

56.90

Halozyme Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
YoY EBITDA Growth	Get a 7-Day Free Trial															64.82	25.46	45.58	69.07	43.04

Halozyme Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Halozyme Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (A: Dec. 2024 )
=	(EBITDA per Share (A: Dec. 2024 )	-	EBITDA per Share (A: Dec. 2023 ))	/	\| EBITDA per Share (A: Dec. 2023 ) \|
=	(4.845	-	3.088)	/	\| 3.088 \|
=	56.90 %

Halozyme Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2025 )
=	(EBITDA per Share (Q: Mar. 2025 )	-	EBITDA per Share (Q: Mar. 2024 ))	/	\| EBITDA per Share (Q: Mar. 2024 )) \|
=	(1.233	-	0.862)	/	\| 0.862 \|
=	43.04 %

Halozyme Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Halozyme Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (FRA:RV7) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

HALO:USA 0J2O:UK

Address

12390 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.halozyme.com

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Halozyme Therapeutics Headlines

No Headlines